2024年美国13-17岁青少年疫苗接种覆盖率——国家青少年免疫调查
分析2024年国家青少年免疫调查数据,16,325名13-17岁青少年中,≥1剂Tdap覆盖率从2023年89.0%升至91.3%,≥1剂MenACWY从88.4%升至90.1%;HPV疫苗接种覆盖率连续第三年稳定,≥1剂为78.2%,完成系列为62.9%。
要点
- ≥1剂Tdap覆盖率为91.3%,≥1剂MenACWY覆盖率为90.1%,均较2023年上升。
- HPV疫苗≥1剂覆盖率为78.2%,完成系列覆盖率为62.9%,连续第三年稳定。
- 非大都市统计区HPV疫苗覆盖率较主要城市低11个百分点,自2016年持续存在。
核心结论
- 2024年青少年Tdap和MenACWY疫苗接种覆盖率较2023年上升,HPV疫苗接种覆盖率连续第三年稳定。
- 自2016年以来,非大都市统计区HPV疫苗接种覆盖率持续低于大都市统计区主要城市。
研究设计与样本
- 分析2024年国家青少年免疫调查(NIS-Teen)数据,确定2024年国家、州和部分地方区域的疫苗接种覆盖率。
- 调查纳入16,325名13-17岁且有足够提供者数据的青少年;家庭应答率为21.0%,完成访谈青少年的足够提供者数据获取率为42.8%。
主要发现
- ≥1剂Tdap覆盖率从2023年的89.0%上升至2024年的91.3%。
- ≥1剂MenACWY覆盖率从2023年的88.4%上升至2024年的90.1%。
- HPV疫苗≥1剂覆盖率为78.2%,完成系列覆盖率为62.9%,连续第三年稳定。
- ≥1剂Tdap覆盖率在39个州达到≥90%,≥1剂MenACWY覆盖率在30个州达到≥90%,≥1剂HPV疫苗覆盖率在26个州和哥伦比亚特区达到≥80%。
- 2024年非大都市统计区与主要城市相比,≥1剂HPV疫苗覆盖率和完成系列覆盖率均低11个百分点。
关键数值与推荐
- 免疫实践咨询委员会推荐青少年常规接种三种疫苗:破伤风类毒素、减量白喉类毒素和无细胞百日咳疫苗(Tdap);四价脑膜炎球菌结合疫苗(MenACWY);人乳头瘤病毒(HPV)疫苗。
临床怎么用
- 卫生保健提供者可通过讨论和推荐疫苗来支持青少年健康,并审查患者记录以确定青少年是否及时接种推荐疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Three vaccines are recommended for routine administration to adolescents by the Advisory Committee on Immunization Practices: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap); quadrivalent meningococcal conjugate vaccine (MenACWY); and human papillomavirus (HPV) vaccine. Data from the 2024 National Immunization Survey-Teen were analyzed to determine national, state, and selected local area vaccination coverage in 2024. Household response rate (21.0%) and receipt of adequate provider data for adolescents with completed interviews (42.8%) were comparable to prior survey years. Among 16,325 adolescents aged 13-17 years with adequate provider data included in the survey, coverage with ≥1 Tdap dose increased from 89.0% in 2023 to 91.3% in 2024; coverage with ≥1 MenACWY dose increased from 88.4% to 90.1%. HPV vaccination coverage remained stable for the third consecutive year; 78.2% of adolescents had received ≥1 dose, and 62.9% were up to date with the HPV vaccination series. Coverage with ≥1 Tdap dose was ≥90% in 39 states, with ≥1 MenACWY dose was ≥90% in 30 states, and with ≥1 dose of HPV vaccine was ≥80% in 26 states and the District of Columbia. Since 2016, lower HPV vaccination coverage in nonmetropolitan statistical areas (MSAs) compared with that in MSA principal cities has persisted, with an 11 percentage point difference in coverage with ≥1 HPV vaccine dose and percentage of adolescents up to date with HPV vaccination in 2024. Health care providers can support adolescent health by discussing and recommending vaccines, as well as reviewing patient records to ascertain whether adolescents are up to date with recommended vaccines.
引用
- Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2024. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40811113. doi:10.15585/mmwr.mm7430a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。